BioInformant

Your Global Leader in Stem Cell Market Research

MENUMENU
  • Blog
    • Interviews
  • News
  • Stem Cells
    • iPS Cells
    • MSCs
    • HSCs
    • Adipose SCs
    • Neural Stem Cells
  • Exosomes
  • CAR-T
  • Cord Blood
  • Shop
    • Products
    • Submit PR
    • Advertise
  • About
    • Testimonials
    • Story
    • Guarantee
    • Contact
  • Home
  • Blog
    • Stem Cells
      • HSCs
      • iPS Cells
      • MSCs
      • Neural Stem Cells
      • Adipose SCs
    • Exosomes
    • Cell Therapy
      • CAR-T
    • Cord Blood
    • Stem Cell News
    • Interviews
  • COVID-19
  • Shop
  • Submit PR
  • Company
    • Advertise
    • Testimonials
    • Story
    • Job Posts
    • Guarantee
    • Privacy Policy
    • Contact
Home » market intelligence » Page 4

[Case Study] ReproCELL as an Early Competitor within the Induced Pluripotent Stem Cell (iPSC) Marketplace

December 9, 2015 By Cade Hildreth (CEO) Leave a Comment

ReproCELL as an Early Competitor within the Induced Pluripotent Stem Cell (iPSC) Marketplace

ReproCELL Enters iPSC Marketplace by 2009

In 2006, Shinya Yamanaka’s lab at Kyoto University in Japan created the first induced pluripotent stem cells (iPSCs) from mouse cells. By 2007, a series of follow-up experiments had been competed at Kyoto University in which human adult cells were transformed into iPSCs. Nearly simultaneously, a research group led by James Thomson at the University of Wisconsin-Madison accomplished the same feat of deriving iPSC lines from human somatic cells.

Just a couple years later in 2009, a forward-thinking company, ReproCELL, entered the iPSC marketplace. At that time, the scientific community was just beginning to explore the cell type, including how to derive, maintain, and differentiate iPSCs.

Established in 2003 as a venture company originating from the University of Tokyo and Kyoto University, ReproCELL was the first company to make induced pluripotent stem cell (iPSC) products commercially available with the launch of its human iPSC-derived cardiomyocytes, which it called “ReproCario.” Other stem cell derived cardiomyocytes are now available commercially from Cellular Dynamics International, GE Healthcare, Cellectis, and others.

ReproCELL’s Commercialization of Induced Pluripotent Stem Cell (iPSC) Products

ReproCELL’s innovation in the area of iPSC commercialization has been driven in part by joint research relationships it established in 2003 with Tokyo University and in 2004 with Kyoto University, the eventual site of iPSC discovery in 2006. Since 2009, ReproCELL has expanded its line of iPSC reagents and iPSC-derived cell lines to include heart, liver, and nerve cells.

The company primarily sells these products as research tools, although they also have the potential for use in toxicology and drug discovery applications. Currently, ReproCELL offers the following iPSC products:

  • Research reagents optimized for human iPSC culture
  • Human iPSC-derived cardiomyocytes, which launched in April of 2009 (the first iPSC product to be sold commercially)
  • Human iPSC-derived neurons, launched in October of 2010
  • Human iPSC-derived hepatocytes, launched in May of 2012
  • Disease model cell generation using human iPS cell technologies

ReproCELL Expands Through Strategic Acquisitions

To date, ReproCELL has furthered its dominance in the area of iPSC products through a series of strategic acquisitions, including acquisition of Reinnervate, BioServe Biotechnologies, and Stemgent, and all occurring in 2014. Over time, ReproCELL has acquired a growing selection of smaller companies, making strategic acquisitions one of its primary techniques for marketplace dominance and company growth.

Most recently, on November 24, 2015, ReproCELL announced that it would be expanding its drug discovery services through its acquisition of the firm Biopta. Based in Glasgow, UK, and Maryland, USA, the Biopta Group describes itself as “providing contract research services to the pharmaceutical industry since 2002 and has established itself as the world leader in the use of fresh functional human tissues to better predict drug activity prior to clinical trials.”

Click here to read the full press release about the event, titled “ReproCELL Acquires Biopta to Expand its Drug Discovery Services.”


To learn more about emerging trends and opportunities within stem cell markets, view our global strategic reports for the stem cell and cord blood industry.

Complete 2015-16 Induced Pluripotent Stem Cell (iPSC) Industry Report
Complete 2015-16 Induced Pluripotent Stem Cell (iPSC) Industry Report
The Market for Stem Cell Biobanking and Storage - Size, Segments, and Trends
The Market for Stem Cell Biobanking and Storage – Size, Segments, and Trends
Mesenchymal Stem Cells - Advances & Applications
Mesenchymal Stem Cells – Advances & Applications

 

 

 

 

 

 

Filed Under: iPS Cells, Stem Cells Tagged With: iPSC, market intelligence, market news, ReproCELL, research products, stem cells, strategy

6 Ways that Market Intelligence Can Benefit Stem Cell Industry Investors

December 4, 2015 By Cade Hildreth (CEO) Leave a Comment

6 Ways that Market Intelligence Can Drive Growth for a Stem Cell Company

Market intelligence has been around for a very long time, but like all fields of study, it has evolved substantially over time. Over the past decade, BioInformant has expanded our market research techniques to include extracting data from massive online databases, delivering electronic surveys to remote regions of the world, and incorporating new social analytics that can capture individual user data as well as aggregate behavior trends on social media platforms.

Therefore, market intelligence is a continually evolving science and one that often benefits from exponential improvement.

Below, I consider the top six ways in which market intelligence can benefit stem cell industry executives and investors. [Read more…]

Filed Under: Adipose SCs, HSCs, iPS Cells, MSCs, Neural Stem Cells, Stem Cells Tagged With: competitive threats, market intelligence, stem cells, strategy

Market Forces Affecting the Cord Blood and Cord Tissue Industry

September 9, 2015 By Cade Hildreth (CEO) Leave a Comment

Market Forces Affecting the Cord Blood and Cord Tissue Industry

Recently released, the “Complete 2015-16 Global Cord Blood Banking Industry Report” explores new clinical trial market data supporting applications for hematopoietic stem cells (HSCs) from cord blood and mesenchymal stem cells (MSCs) from cord tissue. Within this rapidly evolving marketplace, those who choose to commit to understanding current opportunities and threats will be positioned for a substantial strategic advantage.

Because the global cord blood banking industry has matured substantially over the past few years, new market forces have created both serious threats and novel opportunities.   [Read more…]

Filed Under: Cord Blood, HSCs, MSCs Tagged With: cord blood banking, market intelligence, market news, metrics, trends

  • « Previous Page
  • 1
  • 2
  • 3
  • 4

Nanocellect

Marathon Products

Let’s Get Social

  • Facebook
  • Twitter
  • LinkedIn
  • Pinterest
  • Instagram
Menu
  • Blog
  • Stem Cell News
    • Press Releases
  • Stem Cells
    • HSCs
    • iPS Cells
    • MSCs
    • Neural Stem Cells
    • Adipose SCs
  • Exosomes
  • Cell Therapy
    • CAR-T
  • Cord Blood
  • Interviews

Cart

Top Rated Products

  • Job Posting on BioInformant Job Posting on BioInformant.com - Your Perfect Hire Is In Our Audience
    Rated 0 out of 5
    $297
  • U.S. Cord Blood Banking Survey Cord Blood Banking Survey of U.S. Parents [2017]
    Rated 0 out of 5
    $197
  • Exosome Companies 2020 Global Database of Exosome Companies
    Rated 0 out of 5
    $149 $97
My Tweets

BioInformant's World-Class Clients

  • Submit Press Release
  • Advertise
  • Privacy and Terms

Copyright © 2022 · BIOINFORMANT, Your Global Leader in Stem Cell Market Research

| Email: Info@BioInformant.com | Phone: 703-859-7617 |

800 Corporate Drive, Suite 301, Stafford, VA 22554, United States

Disclaimer: All statements made on this website are NOT expressed as medical claims or advice. They are not intended to diagnose, treat, cure or prevent any disease or condition. If you have a health condition or concern, consult your physician or health care provider.